Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 3/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2422527 | 1.00 | USP30 (0.55) | USP30DDB1CRBNFFAR1SRC | |
| SCHEMBL2422530 | 1.00 | USP30 (0.55) | USP30DDB1CRBNFFAR1SRC | |
| SCHEMBL1425502 | 0.94 | USP30 (0.51) | USP30DDB1CRBNFFAR1GPR119 | |
| SCHEMBL12539259 | 0.94 | USP30 (0.51) | USP30DDB1CRBNFFAR1GPR119 | |
| SCHEMBL1425500 | 0.94 | USP30 (0.51) | USP30DDB1CRBNFFAR1GPR119 | |
| SCHEMBL320828 | 0.94 | USP30 (0.52) | USP30DDB1CRBNFFAR1CCNC | |
| SCHEMBL21602904 | 0.92 | USP30 (0.48) | USP30DDB1CRBNFFAR1SRC | |
| SCHEMBL660078 | 0.92 | USP30 (0.49) | USP30DDB1CRBNFFAR1GPR119 | |
| SCHEMBL25238268 | 0.90 | USP30 (0.49) | USP30DDB1CRBNFFAR1EGFR | |
| SCHEMBL15140394 | 0.88 | USP30 (0.52) | USP30DDB1CRBNFFAR1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719592-A1 | BICYCLIC COMPOUNDS FOR KETOHEXOKINASE INHIBITION | Centennial Therapeutics, LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250340533-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | ARRAY BIOPHARMA INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-12264149-B2 | Indazole compounds as kinase inhibitors | TYRA BIOSCIENCES, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| WO-2024253416-A1 | PYRIMIDINE/PYRIDINE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024249612-A1 | BICYCLIC COMPOUNDS FOR KETOHEXOKINASE INHIBITION | CENTENNIAL THERAPEUTICS, LLC (US) | 2024-12-05 | — | — | WO | disclosed |
| US-12071428-B2 | Indazole compounds as kinase inhibitors | TYRA BIOSCIENCES, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240208941-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES, INC. | 2024-06-27 | — | — | US | disclosed |
| US-11999722-B2 | Disubstituted pyrazole compounds | ELI LILLY AND COMPANY (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240109865-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES, INC. | 2024-04-04 | — | — | US | disclosed |
| US-20170362240-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-12-21 | — | — | US | disclosed |
| EP-2265616-B1 | FURO-AND THIENO[3,2-C]PYRIDINES | OSI PHARM INC (US) | 2013-11-20 | — | — | EP | disclosed |
| US-8178668-B2 | 2-aminopyridine kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-8022206-B2 | Furo[3,2-C]pyridines | OSI Pharmaceuticals, LLC (US) | 2011-09-20 | — | — | US | disclosed |
| EP-2265270-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2265616-A1 | FURO-AND THIENO[3,2-C]PYRIDINES | OSI Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009100282-A1 | FURO-AND THIENO[3,2-C] PYRIDINES | OSI PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009099982-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197864-A1 | Furo- and Thieno [3,2-c] Pyridines | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12071428-B2 | Indazole compounds as kinase inhibitors | FGFR1, FGFR2, FGFR3 | USP30 3362/4885DDB1 1526/4885CRBN 1641/4885 |
| US-20240208941-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | USP30 3362/4885DDB1 1526/4885CRBN 1641/4885 |
| US-11999722-B2 | Disubstituted pyrazole compounds | SLC5A2, SLC5A1, GOT2 | USP30 4494/4885DDB1 4540/4885CRBN 4623/4885 |
| US-20170362240-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | USP30 2445/4885DDB1 2741/4885CRBN 913/4885 |
| US-20250340533-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | USP30 3362/4885DDB1 1526/4885CRBN 1641/4885 |
| US-20090197864-A1 | Furo- and Thieno [3,2-c] Pyridines | RET, MET, ERBB2 | USP30 3651/4885DDB1 2782/4885CRBN 414/4885 |
| US-12264149-B2 | Indazole compounds as kinase inhibitors | FGFR1, FGFR2, FGFR3 | USP30 3362/4885DDB1 1526/4885CRBN 1641/4885 |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | FGFR3, FGFR4, FGFR1 | USP30 2688/4885DDB1 1067/4885CRBN 1536/4885 |
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | ERBB2, ABL2, TIE1 | USP30 4472/4885DDB1 3218/4885CRBN 2509/4885 |
| US-20240109865-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | USP30 3362/4885DDB1 1526/4885CRBN 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.